Combination of cadonilimab (anti-PD-1 and CTLA-4 bispecific antibody) with chemotherapy in anti-PD-1-resistant recurrent or metastatic nasopharyngeal carcinoma: An open-label, single-arm, phase II clinical trial

被引：0
|
作者：
Jiang, Y-F. [1 ]
Bei, W-X. [1 ]
Wang, L. [2 ]
Xu, C. [2 ]
Lu, N. [3 ]
Liang, H. [4 ]
Ke, L-R. [3 ]
Ye, Y-F. [5 ]
Fang, T. [1 ]
He, S. [6 ]
Dong, S-H. [1 ]
Liu, Q. [1 ]
Zhang, C. [1 ]
Xia, W. [1 ]
Zhao, C. [1 ]
Xie, C. [7 ]
Liu, G. [8 ]
Xiang, Y-Q. [1 ]
机构：
[1] Sun Yat Sen Univ Canc Ctr, Dept Nasopharyngeal Carcinoma, Guangzhou, Peoples R China
[2] Sun Yat Sen Univ Canc Ctr, Dept Radiat Oncol, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou, Peoples R China
[3] Sun Yat Sen Univ Canc Ctr, Dept Radiol, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou, Peoples R China
[4] Sun Yat Sen Univ Canc Ctr, Dept Nasopharyngeal Carcinoma, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou, Peoples R China
[5] Sun Yat Sen Mem Hosp, Clin Res Design Div, Guangzhou, Peoples R China
[6] Sun Yat Sen Univ, Radiat Oncol, Guang Zhou, Peoples R China
[7] NCI, Thorac & GI Malignancies Branch, Bethesda, MD USA
[8] Sun Yat Sen Univ, Radiotherapy Dept, Guangzhou, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.954
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
893P
引用
收藏
页码：S633 / S634
页数：2
相关论文
共 50 条
  • [31] Efficacy and Safety of AK104, an Anti-PD-1/CTLA-4 Bispecific Antibody, in a Patient with Large Cell Neuroendocrine Carcinoma of the Lung
    Frentzas, S.
    Kwek, K. Y.
    Konpa, A.
    Jin, X.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S506 - S506
  • [32] Recombinant humanized anti-PD-1 monoclonal antibody toripalimab in patients with metastatic urothelial carcinoma: Results of an open-label phase II clinical study Polaris-03.
    Sheng, Xinan
    Chen, Haige
    Hu, Bin
    Yao, Xudong
    Liu, Ziling
    Yao, Xin
    Guo, Hongqian
    Hu, Yi
    Ji, Zhigang
    Luo, Hong
    Shi, Benkang
    Liu, Jiyan
    Wu, Jin
    Zhou, Fangjian
    He, Zhisong
    Fan, Jinhai
    Huang, Yiran
    Guo, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [33] A multicenter, open-label phase Ib/II study of cadonilimab (anti PD-1 and CTLA-4 bispecific antibody) monotherapy in previously treated advanced non-small-cell lung cancer (AK104-202 study)
    Zhao, Yuanyuan
    Ma, Yuxiang
    Fan, Yun
    Zhou, Jianya
    Yang, Nong
    Yu, Qitao
    Zhuang, Wu
    Song, Weifeng
    Wang, Zhongmin Maxwell
    Li, Baiyong
    Xia, Yu
    Zhao, Hongyun
    Zhang, Li
    LUNG CANCER, 2023, 184
  • [34] Surufatinib combined with anti-PD-1/PD-L1 antibody in the second-line or monotherapy in third-line treatment of advanced hepatocellular carcinoma: A single-arm, open-label, multi-center phase II study
    Zhou, F.
    Yang, L.
    Peng, J.
    Xu, H.
    Wu, H.
    Wang, Y.
    Long, X.
    Gao, Q.
    Shi, X.
    Gong, J.
    Hu, J.
    ANNALS OF ONCOLOGY, 2024, 35 : S668 - S668
  • [35] Safety and clinical activity of cadonilimab, an anti PD-1/CTLA-4 bispecific antibody, for patients with persistent, recurrent, or metastatic cervical cancer (R/M CC): A retrospective, real-world study
    Fan, Shi
    Wang, Tao
    Zhang, Qiying
    Wang, Juan
    Su, Jin
    Liu, Zi
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [36] Phase II, Randomized Study of Spartalizumab (PDR001), an Anti-PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer
    Even, Caroline
    Wang, Hung-Ming
    Li, Shau-Hsuan
    Ngan, Roger K-C
    Dechaphunkul, Arunee
    Zhang, Li
    Yen, Chia-Jui
    Chan, Po Chung
    Chakrabandhu, Somvilai
    Ma, Brigette B. Y.
    Tanasanvimon, Suebpong
    Lee, Victor H. F.
    Lou, Pei-Jen
    Li, Zujun
    Spira, Alexander, I
    Sukari, Ammar
    Guigay, Joel
    McCune, Steven
    Gonzalez-Maffe, Juan
    Szpakowski, Sebastian
    Yao, Yao
    Liang, Hongzi
    Mataraza, Jennifer
    Sechaud, Romain
    Manenti, Luigi
    Lim, Darren W-T
    CLINICAL CANCER RESEARCH, 2021, 27 (23) : 6413 - 6423
  • [37] Anti-PD-1 antibody HX008 combined with oxaliplatin plus capecitabine for advanced gastric or esophagogastric junction cancer: a multicenter, single-arm, open-label, phase Ib trial
    Xu, Jianming
    Xu, Nong
    Bai, Yuxian
    Liu, Rongrui
    Mao, Chenyu
    Sui, Hong
    Wang, Xiaofei
    Jiang, Qian
    Dou, Yiwei
    ONCOIMMUNOLOGY, 2021, 10 (01):
  • [38] PD-1 antibody (Camrelizumab) for metastatic EBV positive gastric cancer: A prospective single-arm, open-label, phase 2 trial.
    Qiu, Miaozhen
    Wang, De-Shen
    Sun, Yu-Ting
    Zhao, Qi
    Guan, Wen-Long
    Xu, Rui-hua
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [39] Anti-EGFR antibody plus anti-PD-1 antibody and chemotherapy as a neoadjuvant regimen for patients with locally-advanced penile squamous cell carcinoma: A prospective, single-arm, single-center, phase II clinical trial.
    An, Xin
    Yan, Ru
    Guo, Shengjie
    Xue, Ting
    Ma, Huali
    Chen, Meiting
    Zhou, Fangjian
    Yao, Kai
    Dong, Pei
    Zhang, Zhiling
    Liu, Zhuowei
    Shi, Yanxia
    Han, Hui
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [40] A phase Ib/II trial of AK104 (PD-1/CTLA-4 bispecific antibody) in combination with anlotinib in advanced NSCLC
    Wu, L.
    Chen, B.
    Yao, W.
    Li, X.
    Xiao, Z.
    Liu, H.
    Kong, Y.
    Liu, L.
    Xu, Y.
    Wang, Q.
    Li, J.
    Xu, F.
    Xu, L.
    Li, K.
    Song, W.
    Li, B.
    Wang, Z. M.
    Xia, Y.
    ANNALS OF ONCOLOGY, 2021, 32 : S1006 - S1006
12345